European Journal of Cancer
Volume 41, Issue 4 , Pages 516-522, March 2005

The potential of statins as part of anti-cancer treatment

Department of Medical Oncology, Daniel den Hoed Cancer Center, Erasmus University Medical Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands

Received 15 November 2004; accepted 6 December 2004.

Abstract 

Statins are known to reduce mortality related to cardiovascular diseases. In recent years, evidence has accumulated that statins also exert anti-tumour activity for which numerous potential underlying mechanisms of action have been suggested. Accordingly, several case-control studies showed a reduction in cancer incidence in patients treated with statins. Furthermore, statins interact synergistically with several anti-tumour treatments in preclinical studies. Until now, only a few clinical studies are available that explore the optimal dose, feasibility, and efficacy of statins applied as single agents to control the growth of existing tumours. Studies investigating statins as part of a multi-drug regimen are completely lacking. Nevertheless, the interesting pre-clinical anti-tumour activity of statins combined with a favourable toxicity profile warrant their further development as anti-tumour agents, in particular as part of multi-drug regimens.

Keywords: Statins, Anti-tumour activity, Solid tumours, Drug combinations

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0959-8049(04)00996-7

doi:10.1016/j.ejca.2004.12.009

European Journal of Cancer
Volume 41, Issue 4 , Pages 516-522, March 2005